Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

ALG-135041

Alternative Names: ALG-135041, ALG135041, ALG 135041
Latest Update: 2023-06-21
Latest Update Note: Clinical Trial Update

Product Description

ALG-135041 is a human b-catenin SSO, demonstrated selective inhibition against DNA transactivation activity in the nucleus and showed a better therapeutic window than either siRNAs or ASOs. There is the potential for a significantly improved therapeutic window by precision targeting of only the DNA transactivating region of the multifunctional b-catenin protein. (Sourced from: https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-present-data-its-liver-disease-programs)

Mechanisms of Action: Wnt Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aligos
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Lawrence Blatt
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

06/21/2023

News Article

 Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

06/07/2023

News Article

 Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions